Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ADAG
- Price
- 1.90
- Stock movement up
- +0.21 (10.14%)
- Company name
- Adagene Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 107.46M
- Ent value
- 55.98M
- Price/Sales
- 263.46
- Price/Book
- 1.90
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -13.31%
- 3 year return
- 18.51%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ADAG does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 263.46 |
| Price to Book | 1.90 |
| EV to Sales | 137.24 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 47.13M |
| EPS (TTM) | -0.75 |
| FCF per share (TTM) | -0.45 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 407.87K |
| Gross profit (TTM) | -17.59K |
| Operating income (TTM) | -36.82M |
| Net income (TTM) | -32.94M |
| EPS (TTM) | -0.75 |
| EPS (1y forward) | -0.72 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -4.31% |
| Operating margin (TTM) | -9026.88% |
| Profit margin (TTM) | -8075.15% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 95.67M |
| Net receivables | 31.42K |
| Total current assets | 98.80M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 100.78M |
| Accounts payable | 3.37M |
| Short/Current long term debt | 20.79M |
| Total current liabilities | 39.52M |
| Total liabilities | 44.19M |
| Shareholder's equity | 56.59M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -20.06M |
| Capital expenditures (TTM) | 18.82K |
| Free cash flow (TTM) | -20.08M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -58.20% |
| Return on Assets | -32.68% |
| Return on Invested Capital | -45.30% |
| Cash Return on Invested Capital | -27.62% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.15 |
| Daily high | 2.33 |
| Daily low | 2.13 |
| Daily Volume | 87K |
| All-time high | 29.60 |
| 1y analyst estimate | 9.64 |
| Beta | 0.74 |
| EPS (TTM) | -0.75 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 3 Dec 2025 |
Downside potential
Loading...
Downside potential data
| ADAG | S&P500 | |
| Current price drop from All-time high | -92.30% | -1.46% |
| Highest price drop | -96.96% | -56.47% |
| Date of highest drop | 31 Oct 2022 | 9 Mar 2009 |
| Avg drop from high | -83.68% | -10.99% |
| Avg time to new high | 380 days | 12 days |
| Max time to new high | 1137 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
107.46M
Marketcap category
Small-cap
Description
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Employees
138
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page